Investigation Report on Chinese Sevoflurane Market, 2021-2025
Request Sample
Pre-order Enquiry
Request Customization
Check Discounts
Sevoflurane is an inhalation general anesthetic and also the main inhalation anesthetic at this stage. Inhaled Sevoflurane was originally developed by Abbott and entered the Chinese market in 1996.
In the Chinese market, with the prevalence of chronic diseases, the improvement of the medical system, and the intensification of aging in some regions, the number of operations has increased. Moreover, due to the therapeutic advantages of Sevoflurane, it dominates the anesthesia market. Therefore, Researcher predicts that the sales of Sevoflurane will increase in the future.
According to Researcher's market research, the sales revenue of Sevoflurane in the Chinese market has increased from 2017 to 2019, and reached CNY729.39 million in 2019. The CAGR for Sevoflurane from 2016 to 2019 is about 2.41%. In 2020, due to the COVID-19 epidemic, the number of surgeries decreased. Thus, the sales of Sevoflurane decreased accordingly. However, Researcher analyzes that as the epidemic has improved, the sales of Sevoflurane in the Chinese market will have a recovery growth in 2021-2025.
Topics Covered:
-The impact of COVID-19 on China's sevoflurane market
- Sales value and volume of China's sevoflurane 2016-2020
- Competitive landscape of China's sevoflurane market
- Prices of sevoflurane in China
- Prices of sevoflurane in China by regions and manufacturers
- Analysis on factors affecting the development of China's sevoflurane market
- Prospect of China's sevoflurane market from 2021 to 2025
In the Chinese market, with the prevalence of chronic diseases, the improvement of the medical system, and the intensification of aging in some regions, the number of operations has increased. Moreover, due to the therapeutic advantages of Sevoflurane, it dominates the anesthesia market. Therefore, Researcher predicts that the sales of Sevoflurane will increase in the future.
According to Researcher's market research, the sales revenue of Sevoflurane in the Chinese market has increased from 2017 to 2019, and reached CNY729.39 million in 2019. The CAGR for Sevoflurane from 2016 to 2019 is about 2.41%. In 2020, due to the COVID-19 epidemic, the number of surgeries decreased. Thus, the sales of Sevoflurane decreased accordingly. However, Researcher analyzes that as the epidemic has improved, the sales of Sevoflurane in the Chinese market will have a recovery growth in 2021-2025.
Topics Covered:
-The impact of COVID-19 on China's sevoflurane market
- Sales value and volume of China's sevoflurane 2016-2020
- Competitive landscape of China's sevoflurane market
- Prices of sevoflurane in China
- Prices of sevoflurane in China by regions and manufacturers
- Analysis on factors affecting the development of China's sevoflurane market
- Prospect of China's sevoflurane market from 2021 to 2025
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Details
CRI-17947247
09-Apr-2021
50
09-Apr-2021
50
License
